Loading…
Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease
Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuc...
Saved in:
Published in: | AIMS neuroscience 2024, Vol.11 (3), p.312-340 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 340 |
container_issue | 3 |
container_start_page | 312 |
container_title | AIMS neuroscience |
container_volume | 11 |
creator | Kumar, Anmol Gupta, Ajay Kumar Singh, Prashant Kumar |
description | Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life. |
doi_str_mv | 10.3934/Neuroscience.2024020 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_60b4ed5c0b9c4b049298abd2552c7852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_60b4ed5c0b9c4b049298abd2552c7852</doaj_id><sourcerecordid>3118837181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2690-cce0c2de483c06fa5be031a439cdb3fa08cbbe86ecfc0b1ee285459bf2c454433</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhiMEolXpP0DIN7hs668k9gmhio9KVeEAZ8seT7YuiR3sZKX-ewy7rbYn2-N3Ho_1NM1bRi-EFvLyFtecCgSMgBecckk5fdGcctGLTa97_vJof9Kcl3JPKWWS953Wr5sToaVgvNOnzfY27XAkM-YyIyxhhyQNZLnDbGdclwBkSn4dsZAlkRrNkCastSVlYqMnMcX9oTxM85KmQkIkP2z-HWJJ8X0hPhS0Bd80rwY7Fjw_rGfNry-ff15929x8_3p99elmA3UcugFACtyjVAJoN9jWIRXMSqHBOzFYqsA5VB3CANQxRK5a2Wo3cJCtlEKcNdd7rk_23sw5TDY_mGSD-V9IeWtsrt8a0XTUSfRt5WiQjkrNtbLO87bl0KuWV9bHPWte3YQeMC7Zjs-gz29iuDPbtDOMSdV1TFbChwMhpz8rlsVMoQCOo42Y1mIEY0qJnilWo3IfhSq2ZBye3mHU_HNujp2bg_Pa9u54xqemR8PiL-TdruA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118837181</pqid></control><display><type>article</type><title>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</title><source>PubMed Central</source><creator>Kumar, Anmol ; Gupta, Ajay Kumar ; Singh, Prashant Kumar</creator><creatorcontrib>Kumar, Anmol ; Gupta, Ajay Kumar ; Singh, Prashant Kumar</creatorcontrib><description>Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.</description><identifier>ISSN: 2373-7972</identifier><identifier>ISSN: 2373-8006</identifier><identifier>EISSN: 2373-7972</identifier><identifier>DOI: 10.3934/Neuroscience.2024020</identifier><identifier>PMID: 39431269</identifier><language>eng</language><publisher>United States: AIMS Press</publisher><subject>ablative surgery ; deep brain stimulation (dbs) ; dopamine precursor ; motor and non-motor symptoms ; parkinson's disease (pd) ; Review</subject><ispartof>AIMS neuroscience, 2024, Vol.11 (3), p.312-340</ispartof><rights>2024 the Author(s), licensee AIMS Press.</rights><rights>2024 the Author(s), licensee AIMS Press 2024 the Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486614/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486614/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39431269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Anmol</creatorcontrib><creatorcontrib>Gupta, Ajay Kumar</creatorcontrib><creatorcontrib>Singh, Prashant Kumar</creatorcontrib><title>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</title><title>AIMS neuroscience</title><addtitle>AIMS Neurosci</addtitle><description>Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.</description><subject>ablative surgery</subject><subject>deep brain stimulation (dbs)</subject><subject>dopamine precursor</subject><subject>motor and non-motor symptoms</subject><subject>parkinson's disease (pd)</subject><subject>Review</subject><issn>2373-7972</issn><issn>2373-8006</issn><issn>2373-7972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1v1DAQhiMEolXpP0DIN7hs668k9gmhio9KVeEAZ8seT7YuiR3sZKX-ewy7rbYn2-N3Ho_1NM1bRi-EFvLyFtecCgSMgBecckk5fdGcctGLTa97_vJof9Kcl3JPKWWS953Wr5sToaVgvNOnzfY27XAkM-YyIyxhhyQNZLnDbGdclwBkSn4dsZAlkRrNkCastSVlYqMnMcX9oTxM85KmQkIkP2z-HWJJ8X0hPhS0Bd80rwY7Fjw_rGfNry-ff15929x8_3p99elmA3UcugFACtyjVAJoN9jWIRXMSqHBOzFYqsA5VB3CANQxRK5a2Wo3cJCtlEKcNdd7rk_23sw5TDY_mGSD-V9IeWtsrt8a0XTUSfRt5WiQjkrNtbLO87bl0KuWV9bHPWte3YQeMC7Zjs-gz29iuDPbtDOMSdV1TFbChwMhpz8rlsVMoQCOo42Y1mIEY0qJnilWo3IfhSq2ZBye3mHU_HNujp2bg_Pa9u54xqemR8PiL-TdruA</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Kumar, Anmol</creator><creator>Gupta, Ajay Kumar</creator><creator>Singh, Prashant Kumar</creator><general>AIMS Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2024</creationdate><title>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</title><author>Kumar, Anmol ; Gupta, Ajay Kumar ; Singh, Prashant Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2690-cce0c2de483c06fa5be031a439cdb3fa08cbbe86ecfc0b1ee285459bf2c454433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>ablative surgery</topic><topic>deep brain stimulation (dbs)</topic><topic>dopamine precursor</topic><topic>motor and non-motor symptoms</topic><topic>parkinson's disease (pd)</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Anmol</creatorcontrib><creatorcontrib>Gupta, Ajay Kumar</creatorcontrib><creatorcontrib>Singh, Prashant Kumar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>AIMS neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Anmol</au><au>Gupta, Ajay Kumar</au><au>Singh, Prashant Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease</atitle><jtitle>AIMS neuroscience</jtitle><addtitle>AIMS Neurosci</addtitle><date>2024</date><risdate>2024</risdate><volume>11</volume><issue>3</issue><spage>312</spage><epage>340</epage><pages>312-340</pages><issn>2373-7972</issn><issn>2373-8006</issn><eissn>2373-7972</eissn><abstract>Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms. Epidemiological data indicates a rise in PD cases worldwide, which highlights the need for effective treatments. Pathophysiological insights point out the involvement of various factors in PD progression, such as dopamine dysregulation, genetic mutations, oxidative stress, mitochondrial damage, alpha-synuclein aggregation, and neuroinflammation. Although current treatments, which include dopamine precursors, monoamine oxidase (MAO) inhibitors, and non-dopaminergic drugs, can alleviate motor symptoms, they are not effective in preventing disease progression or managing non-motor symptoms. Additionally, they can lead to adverse effects and become less effective over time. Novel therapeutic approaches, including cell-based therapies, gene therapies, targeted drug delivery therapies, and magnetic field therapies, are promising in improving symptom management and providing personalized treatment. Additionally, emerging therapies that target alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation may have potential disease-modifying effects. To sum up, for dealing with the multiple aspects of PD, there is a great need to come up with new and creative therapeutic approaches that not only relieve symptoms, but also prevent the progression of disease and non-motor symptoms. The progress made in comprehending the underlying mechanisms of PD provides optimism for developing successful treatments that can enhance the outcomes and quality of life.</abstract><cop>United States</cop><pub>AIMS Press</pub><pmid>39431269</pmid><doi>10.3934/Neuroscience.2024020</doi><tpages>29</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2373-7972 |
ispartof | AIMS neuroscience, 2024, Vol.11 (3), p.312-340 |
issn | 2373-7972 2373-8006 2373-7972 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_60b4ed5c0b9c4b049298abd2552c7852 |
source | PubMed Central |
subjects | ablative surgery deep brain stimulation (dbs) dopamine precursor motor and non-motor symptoms parkinson's disease (pd) Review |
title | Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T20%3A23%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20perspective%20of%20therapeutic%20modules%20to%20overcome%20motor%20and%20nonmotor%20symptoms%20in%20Parkinson's%20disease&rft.jtitle=AIMS%20neuroscience&rft.au=Kumar,%20Anmol&rft.date=2024&rft.volume=11&rft.issue=3&rft.spage=312&rft.epage=340&rft.pages=312-340&rft.issn=2373-7972&rft.eissn=2373-7972&rft_id=info:doi/10.3934/Neuroscience.2024020&rft_dat=%3Cproquest_doaj_%3E3118837181%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2690-cce0c2de483c06fa5be031a439cdb3fa08cbbe86ecfc0b1ee285459bf2c454433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3118837181&rft_id=info:pmid/39431269&rfr_iscdi=true |